Cixutumumab

Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer[1].

Product Specifications

CAS Number

[947687-12-9]

Product Name Alternative

IMC-A12; NSC742460

UNSPSC

12352203

Target

IGF-1R

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cixutumumab.html

Purity

99.63

Solubility

10 mM in DMSO

Smiles

[Cixutumumab]

Molecular Weight

(150 kDa)

References & Citations

[1]Houghton PJ, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Jul 1;54 (7) :921-6.